Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.63 |
| ▸ | ALPI | P09923 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | XIAP | P98170 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | FYN | P06241 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | TPH1 | P17752 | 2/20 | 0.54 |
| ▸ | GRB2 | P62993 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12611746 | 1.00 | SLC7A5 (0.65) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL2310526 | 0.86 | SLC7A5 (0.83) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL16577961 | 0.84 | SLC7A5 (0.62) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL12611747 | 0.84 | SLC7A5 (0.62) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL8237040 | 0.82 | SLC7A5 (0.61) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL5608012 | 0.82 | SLC7A5 (0.61) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL5608007 | 0.82 | SLC7A5 (0.61) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL12831404 | 0.81 | SLC7A5 (0.65) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL12611650 | 0.81 | SLC7A5 (0.65) | SLC7A5PTGS1ALPIPKMXIAP | |
| SCHEMBL2265485 | 0.81 | SLC7A5 (0.59) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. | 2024-07-16 | — | — | US | disclosed |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20220411469-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | AMBRX, INC. (US) | 2022-12-29 | — | — | US | disclosed |
| WO-2022211624-A1 | TAILOR-MADE FUNCTIONALIZED SELF-ASSEMBLED PEPTIDE (NANO)FIBERS AND HYDROGELS, AND METHODS, USES AND KITS RELATED THERETO | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2022-10-06 | — | — | WO | disclosed |
| US-20220033518-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATES | AMBRX,INC. (US) | 2022-02-03 | — | — | US | disclosed |
| US-20210277056-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | AMBRX, INC. (US) | 2021-09-09 | — | — | US | disclosed |
| US-10954270-B2 | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives | AMBRX, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-10800856-B2 | Prostate-specific membrane antigen antibody drug conjugates | AMBRX, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-10208123-B2 | Anti-CD70 antibody drug conjugates | AMBRX, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-9796754-B2 | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives | AMBRX, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-3170821-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | Ambrx, Inc. (US) | 2017-05-24 | — | — | EP | disclosed |
| US-20150152187-A1 | Anti-PSMA Antibodies Conjugated to Nuclear Receptor Ligand Polypeptides | AMBRX, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150152190-A1 | Prostate-Specific Membrane Antigen Antibody Drug Conjugates | AMBRX, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150141624-A1 | Anti-CD70 Antibody Drug Conjugates | AMBRX, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150080559-A1 | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acid Linked Dolastatin Derivatives | AMBRX, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| WO-2012166560-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | AMBRX, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012166559-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | AMBRX, INC. (US) | 2012-12-06 | — | — | WO | disclosed |
| US-20090240029-A1 | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides | AMBRX, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-20090240029-A1 | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides | AMBRX, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| WO-2007079130-A2 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES | AMBRX, INC. (US) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411469-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | DDOST, DAD1, PTMS | SLC7A5 127/4885PTGS1 1295/4885ALPI 3508/4885 |
| US-12037405-B2 | Anti-CD70 antibody drug conjugates | CD74, CD63, CD47 | SLC7A5 264/4885PTGS1 4544/4885ALPI 2388/4885 |
| US-20150141624-A1 | Anti-CD70 Antibody Drug Conjugates | CD74, CD63, CD47 | SLC7A5 264/4885PTGS1 4544/4885ALPI 2388/4885 |
| US-20150152187-A1 | Anti-PSMA Antibodies Conjugated to Nuclear Receptor Ligand Polypeptides | AR, PSMA1, NR2E3 | SLC7A5 1727/4885PTGS1 3129/4885ALPI 2118/4885 |
| US-10208123-B2 | Anti-CD70 antibody drug conjugates | CD74, CD63, CD47 | SLC7A5 264/4885PTGS1 4544/4885ALPI 2388/4885 |
| US-10800856-B2 | Prostate-specific membrane antigen antibody drug conjugates | KLK3, PTMS, DDOST | SLC7A5 545/4885PTGS1 1909/4885ALPI 1555/4885 |
| US-20210277056-A1 | COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID LINKED DOLASTATIN DERIVATIVES | DDOST, DAD1, PTMS | SLC7A5 127/4885PTGS1 1295/4885ALPI 3508/4885 |
| US-10954270-B2 | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives | DDOST, DAD1, PTMS | SLC7A5 127/4885PTGS1 1295/4885ALPI 3508/4885 |
| US-20230295320-A1 | Anti-CD70 Antibody Drug Conjugates | CD63, CD74, CD99 | SLC7A5 221/4885PTGS1 4492/4885ALPI 1996/4885 |
| US-20220033518-A1 | PROSTATE-SPECIFIC MEMBRANE ANTIGEN ANTIBODY DRUG CONJUGATES | KLK3, PTMS, DDOST | SLC7A5 545/4885PTGS1 1909/4885ALPI 1555/4885 |
| US-20150152190-A1 | Prostate-Specific Membrane Antigen Antibody Drug Conjugates | KLK3, PTMS, DDOST | SLC7A5 545/4885PTGS1 1909/4885ALPI 1555/4885 |
| US-20090240029-A1 | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides | DNPEP, DDC, PTMS | SLC7A5 409/4885PTGS1 3564/4885ALPI 3581/4885 |
| US-20150080559-A1 | Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acid Linked Dolastatin Derivatives | DDOST, DAD1, PTMS | SLC7A5 132/4885PTGS1 1348/4885ALPI 3466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.